Chris Howerton
Stock Analyst at Jefferies
(2.45)
# 2,352
Out of 4,711 analysts
74
Total ratings
42.37%
Success rate
12.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $27.90 | +183.15% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.80 | +122.22% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.65 | +54.06% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $20 → $22 | $0.34 | +6,351.61% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $8.91 | +7,980.81% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.53 | -67.32% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $10.64 | -6.02% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.50 | -20.00% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $10.31 | +6.69% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $33.21 | +20.45% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $34.28 | +77.95% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $90.73 | -0.80% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $5 | $4.82 | +3.73% | 4 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.78 | +151.05% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $6.90 | +1,726.09% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.77 | +2,494.03% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $25.14 | +162.53% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $0.84 | +3,484.66% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $8.75 | +151.43% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.97 | +607.07% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.59 | +1,283.65% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.03 | +2,133.01% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $16.87 | +24.48% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $4 → $29 | $0.92 | +3,067.67% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.11 | +5,305.41% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $51.40 | -68.87% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $41.49 | -34.92% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.18 | +13,233.33% | 1 | May 26, 2020 |
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $27.90
Upside: +183.15%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.80
Upside: +122.22%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.65
Upside: +54.06%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $20 → $22
Current: $0.34
Upside: +6,351.61%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $8.91
Upside: +7,980.81%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.53
Upside: -67.32%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $10.64
Upside: -6.02%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.50
Upside: -20.00%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $10.31
Upside: +6.69%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $33.21
Upside: +20.45%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $34.28
Upside: +77.95%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $90.73
Upside: -0.80%
Mar 2, 2022
Upgrades: Buy
Price Target: $1 → $5
Current: $4.82
Upside: +3.73%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.78
Upside: +151.05%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $6.90
Upside: +1,726.09%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.77
Upside: +2,494.03%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $25.14
Upside: +162.53%
Aug 24, 2021
Initiates: Buy
Price Target: $30
Current: $0.84
Upside: +3,484.66%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $8.75
Upside: +151.43%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $2.97
Upside: +607.07%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.59
Upside: +1,283.65%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.03
Upside: +2,133.01%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $16.87
Upside: +24.48%
Aug 11, 2020
Upgrades: Buy
Price Target: $4 → $29
Current: $0.92
Upside: +3,067.67%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.11
Upside: +5,305.41%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $51.40
Upside: -68.87%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $41.49
Upside: -34.92%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.18
Upside: +13,233.33%